Added to YB: 2024-01-02
Pitch date: 2024-01-02
PYXS [bullish]
Pyxis Oncology, Inc.
+52.2%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Market Cap
$249.4M
Pitch Price
$2.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.88
P/E
-2.13
EV/Sales
21.22
Sector
Biotechnology
Category
N/A
Show full summary:
$PYXS - I like the PYX-201 approach
$PYXS bullish on PYX-201 targeting tumor stroma, especially in pancreatic cancer. Potential as combo agent if early signals positive. Boehringer Ingelheim strategic investment boosts confidence. Watch for mid-2024 data. High-risk play.
Read full article (1 min)